MedTrace Logo

A Study of Baricitinib (LY3009104) in Participants With COVID-19

NCT04421027 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1525

Last updated 2022-07-28

Study results available
· View outcomes & findings →

Summary

The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.

Conditions

Interventions

DRUG

Baricitinib

Given orally

DRUG

Placebo

Given orally

Sponsors & Collaborators

Principal Investigators

  • Call 1-877-CTLILLY (1-877-265-4559 or 1-317-615-4559) Mon - Fri 9AM - 5PM Eastern Time (UTC/GMT - 5 hours, EST) · Eli Lilly and Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-12
Primary Completion
2021-02-12
Completion
2021-06-10
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Brazil
  • Germany
  • India
  • Italy
  • Japan
  • Mexico
  • Puerto Rico
  • Russia
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04421027 on ClinicalTrials.gov